Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KLS-116
- Development stage
- Preclinical
- Lead developer
- MetalloBio
- Modality
- Small Molecules
01
Overview
KLS-116 is a preclinical-stage systemic antibiotic being developed by MetalloBio for the treatment of complicated bacterial infections. It is the lead candidate from the company's Series 1 compounds, which are based on a novel ruthenium-nitrogen complex platform. The drug features a modular design built around an inert metal ion core and exhibits a multi-modal mechanism of action with at least two distinct killing activities. This unique approach is designed to provide high potency against pathogens while eliciting minimal emergence of resistance. MetalloBio was spun out from the University of Sheffield in 2021 to commercialize this inorganic chemistry-based antimicrobial technology.
Beyond the preview
Go deeper on KLS-116.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KLS-116.